Metacrine has announced it has secured $36 million in funding.
Metacrine, based in San Diego, Calif., is a biotechnology company focused on advancing research in nuclear hormone receptors for treatment of metabolic diseases originated at the Salk Institute for Biological Studies.
The series A financing round included participation from Arch Venture Partners, EcoR1 Capital, Polaris Partners and venBio.
